Common Side Effects from Long-Term Use
Ozempic (semaglutide) often causes gastrointestinal issues like nausea, vomiting, diarrhea, and constipation, which affect up to 20-30% of users in trials and may persist or worsen over time.[1][2] These stem from its GLP-1 receptor agonist action, slowing gastric emptying.
Risk of Pancreatitis and Gallbladder Problems
Long-term use links to acute pancreatitis (rare, ~1% in studies) and gallbladder events like cholelithiasis, with odds rising after 1-2 years.[2][3] FDA warnings note these risks, based on post-marketing data showing higher incidence versus placebo.
Thyroid Cancer Concerns
Animal studies showed thyroid C-cell tumors with semaglutide; human risk remains unclear but prompted a boxed warning.[1] No definitive long-term human data confirms this, though monitoring is advised for those with family history.
Muscle Loss and Weight Regain
Extended use leads to 20-40% of weight loss coming from lean muscle, potentially causing sarcopenia in older adults.[4] Upon stopping, users regain ~2/3 of weight within a year, per STEP trials, due to metabolic adaptations.[2]
Hypoglycemia and Cardiovascular Monitoring
Though low overall, hypoglycemia risk increases with insulin or sulfonylureas long-term.[1] Benefits like reduced major adverse cardiac events (14% relative risk reduction) hold in trials up to 5 years, but kidney function needs watching for rare acute injury.[3]
Bone Health and GI Complications
Some data suggest reduced bone mineral density after 1+ years, raising fracture risk, especially in postmenopausal women.[5] Long-term users report gastroparesis-like symptoms, with lawsuits alleging ileus and bowel obstruction.[6]
Dependency and Access Issues
Patients may develop reliance for weight control, facing rebound effects off-drug. Supply shortages and high costs ($900+/month without insurance) limit long-term access.[7]
[1]: Ozempic Prescribing Information (FDA)
[2]: NEJM STEP Trials (2021-2023)
[3]: LEADER Trial Follow-Up (NEJM, 2019)
[4]: JAMA Muscle Loss Analysis (2023)
[5]: Diabetes Care Bone Density Study (2022)
[6]: FDA Adverse Event Reporting (FAERS, 2023)
[7]: GoodRx Pricing Data (2024)